Kidney Disease Clinical Trialists 8th Edition 2024

The Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop is designed for a select group of professionals involved in kidney disease research and clinical trials. The target audience includes:

• Nephrologists
• Clinical trialists
• Principal investigators
• Statisticians
• Researchers from academia
• Professionals from R&D pharma and device companies
• Representatives from regulatory bodies like NIH, EMA, PMDA, and FDA
• Payers
• Patient advocates

This workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation of therapeutic strategies for kidney disease.

+ Topics:

• SESSION 1 EGFR SLOPE VS EGFR DELTA AS AN ENDPOINT PROS AND CONS.mp4
• SESSION 2 COMBINATION THERAPY IN CKD.mp4
• SESSION 3 Focus on IGAN.mp4
• SESSION 4 Shifting earlg deveIOpment trials from the EGFR UACR ratio paradigm to a multiplexed biomarker enabled strategy.mp4
• SESSION 5 Are simplified consents desirable achievable.mp4
• SESSION 6 Dialysis and Vascular Access.mp4
• SESSION 7 How to assess the renal benefit of weight loss drugs (i.e.drugs that can affect lean bodg mass).mp4
• SESSION 8 Endpoints in AKI trials to guide generation of Core Outcome data Set.mp4
• SESSION 9 Developing Core Outcomes Sets in AKI trials.mp4